

MEDINEX LIMITED

Condensed Interim Financial Statements For the Six Months and Full Year Ended 31 March 2022

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "Sponsor") in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.

Table of Contents

A. Condensed Interim and Full Year Consolidated Statement of Profit or Loss and Other Comprehensive Income.....	2
B. Statements of Financial Position of the Group and the Company	4
C. Aggregate Amount of Group’s Borrowings and Debt securities.....	6
D. Condensed Statements of Changes in Equity	7
E. Condensed Full Year Statements of Cash Flows.....	10
F. Notes to the Condensed Interim Consolidated Financial Statements.....	12
G. Other Information Required Pursuant to Appendix 7C of the Catalist Rules.....	35

A. Condensed Interim and Full Year Consolidated Statement of Profit or Loss and Other Comprehensive Income

		Group					
		6 months ended 31 March 2022 (Unaudited)	6 months ended 31 March 2021 (Unaudited)	Change	12 months ended 31 March 2022 (Unaudited)	12 months ended 31 March 2021 (Audited)	Change
Note		S\$'000	S\$'000	%	S\$'000	S\$'000	%
	Revenue	6,187	5,804	6.60	11,993	10,785	11.20
	Other item of income						
	Other income	557	1,929	(71.12)	1,619	2,515	(35.63)
	Items of expense						
	Changes in inventories	75	(108)	N.M.	(78)	(275)	N.M.
	Inventories and consumables	(1,810)	(1,584)	14.27	(3,348)	(2,850)	17.47
	Employee benefits expense	(2,442)	(2,469)	(1.09)	(4,490)	(4,287)	4.74
	Depreciation and amortisation expenses	(351)	(342)	2.63	(650)	(693)	(6.20)
	Loss allowance on trade receivables	(212)	(279)	(24.01)	(231)	(283)	(18.37)
	Other expenses	(971)	(605)	60.50	(1,459)	(994)	46.78
	Finance costs	(41)	(46)	(10.87)	(86)	(72)	19.44
	Share of results of joint venture, net of tax	(13)	(42)	(69.05)	(3)	10	N.M
	Profit before income tax	978	2,258	(56.69)	3,266	3,856	(15.30)
	Income tax expense	(178)	(118)	50.85	(370)	(303)	22.11
	Profit for the financial period/year, representing total comprehensive income for the financial period/year	800	2,140	(62.62)	2,896	3,553	(18.49)

A. **Condensed Interim and Full Year Consolidated Statement of Profit or Loss and Other Comprehensive Income(cont'd)**

Note	Group					
	6 months ended 31 March 2022 (Unaudited)	6 months ended 31 March 2021 (Unaudited)	Change	12 months ended 31 March 2022 (Unaudited)	12 months ended 31 March 2021 (Audited)	Change
	S\$'000	S\$'000	%	S\$'000	S\$'000	%
<i>Other comprehensive income</i>						
Foreign currency translation differences	(1)	1	N.M	(7)	1	N.M
Other comprehensive income for the financial period/year, net of tax	(1)	1	N.M	(7)	1	N.M
Total comprehensive income for the financial period/year	798	2,141	(62.73)	2,889	3,554	(18.71)
Profit attributable to:						
Owners of the Company	755	2,098	(64.01)	2,807	3,493	(19.64)
Non-controlling interests	45	42	7.14	89	60	48.33
	800	2,140	(62.62)	2,896	3,553	(18.49)
Profit and total comprehensive income attributable to:						
Owners of the Company	753	2,099	(64.13)	2,800	3,493	(19.84)
Non-controlling interests	45	42	7.14	89	60	48.33
	798	2,141	(62.73)	2,889	3,553	(18.69)

N.M. – not meaningful

B. Statements of Financial Position of the Group and the Company

	Group		Company	
	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Note	S\$'000	S\$'000	S\$'000	S\$'000
ASSETS				
Non-current assets				
Plant and equipment	256	136	41	51
Right-of-use (“ROU”) assets	865	1,444	-	-
Intangible assets	12 6,686	7,098	-	-
Investment in subsidiaries	13 -	-	10,597	10,884
Investment in joint ventures	208	321	195	286
Financial assets at fair value through profit or loss (“FVTPL”)	11 5,573	4,321	5,573	4,320
Other receivables	-	589	-	589
	13,588	13,909	16,406	16,130
Current assets				
Inventories	484	562	-	-
Trade and other receivables	2,121	2,188	207	209
Contract assets	63	15	-	-
Prepayments	386	100	426	61
Fixed deposit	516	1,550	-	1,038
Cash and bank balances	5,823	5,107	3,067	1,243
	9,393	9,522	3,700	2,551
Total assets	22,981	23,431	20,106	18,681
EQUITY AND LIABILITIES				
Equity				
Share capital	17 14,163	14,163	14,163	14,163
Other reserves	(1,540)	(1,540)	408	408
Foreign currency translation reserve	(6)	1	-	-
Retained earnings	4,636	4,033	2,803	1,869
Equity attributable to owners of the parent	17,253	16,657	17,374	16,440
Non-controlling interests	223	269	-	-
Total equity	17,476	16,927	17,374	16,440

B. Statements of Financial Position of the Group and the Company (Cont'd)

	Group		Company	
	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021
	Note	S\$'000	S\$'000	S\$'000
Non-current liabilities				
Other payables		-	1,735	-
Lease liabilities		418	-	-
Bank borrowings	16	1,779	-	-
Provisions		31	-	-
Deferred tax liabilities		37	-	-
		2,265	1,735	-
Current liabilities				
Trade and other payables		1,470	987	2,231
Contract liabilities		434	-	-
Lease liabilities		411	-	-
Bank borrowings	16	496	10	10
Current income tax payables		428	-	-
		3,239	997	2,241
Total liabilities		5,505	2,732	2,241
Total equity and liabilities		22,981	20,106	18,681

C. Aggregate Amount of Group's Borrowings and Debt securities

Amount repayable in one year or less, or on demand

As at 31-Mar-22			As at 31-Mar-21		
Secured		Unsecured	Secured		Unsecured
S\$'000		S\$'000	S\$'000		S\$'000
2		496	54		218

Amount repayable after one year

As at 31-Mar-22			As at 31-Mar-21		
Secured		Unsecured	Secured		Unsecured
S\$'000		S\$'000	S\$'000		S\$'000
-		1,779	28		2,292

Details of any collaterals

The Group's obligations under finance leases are secured on the plant and equipment purchased under finance lease arrangements.

D. Condensed Statements of Changes in Equity

Group	Share capital	Other reserves	Foreign currency translation reserve	Retained earnings	Equity attributable to owners of the Company	Non-controlling interests	Total equity
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Balance at 1 April 2021	14,163	(1,540)	1	4,033	16,657	269	16,927
Other comprehensive income							
Foreign currency translation differences							
- foreign operations	-	-	(7)	-	(7)	-	(7)
Profit for the financial year	-	-	-	2,807	2,807	89	2,896
Total comprehensive income for the financial year	-	-	(7)	2,807	2,800	89	2,889
Distribution to owners							
Dividends	-	-	-	(2,204)	(2,204)	-	(2,204)
Total transactions with owners	-	-	-	(2,204)	(2,204)	-	(2,204)
Transactions with non-controlling interest							
Dividends	-	-	-	-	-	(135)	(135)
Total transactions with non-controlling interest	-	-	-	-	-	(135)	(135)
Balance at 31 March 2022	14,163	(1,540)	(6)	4,636	17,253	223	17,476

D. Condensed Statements of Changes in Equity (Cont'd)

Group	Share capital	Other reserves	Foreign currency translation reserve	Retained earnings	Equity attributable to owners of the Company	Non-controlling interests	Total equity
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Balance at 1 April 2020	14,163	(1,540)	-	1,642	14,265	344	14,609
Other comprehensive income							
Foreign currency translation differences							
- foreign operations	-	-	1	-	1	-	1
Profit for the financial year	-	-	-	3,493	3,493	60	3,555
Total comprehensive income for the financial year	-	-	1	3,493	3,495	60	3,555
Distribution to owners							
Dividends	-	-	-	(1,102)	(1,102)	-	(1,102)
Total transactions with owners	-	-	-	(1,102)	(1,102)	-	(1,102)
Transactions with non-controlling interest							
Dividends	-	-	-	-	-	(135)	(135)
Total transactions with non-controlling interest	-	-	-	-	-	(135)	(135)
Balance at 31 March 2021	14,163	(1,540)	1	4,033	16,657	269	16,927

D. Condensed Statements of Changes in Equity (Cont'd)

Statements of Changes in Equity

Company

	Share capital S\$'000	Other reserves S\$'000	Retained earnings S\$'000	Total equity S\$'000
Balance as 1 April 2021	14,163	408	1,869	16,440
Profit for the financial year	-	-	3,138	3,138
Total comprehensive income for the financial year	-	-	3,138	3,138
Distributions to owners				
Dividends	-	-	(2,204)	(2,204)
Total transactions with owners	-	-	(2,204)	(2,204)
Balance at 31 March 2022	14,163	408	2,803	17,374
Balance as 1 April 2020	14,163	408	70	14,641
Profit for the financial year	-	-	2,900	2,900
Total comprehensive income for the financial year	-	-	2,900	2,900
Distributions to owners				
Dividends	-	-	(1,102)	(1,102)
Total transactions with owners	-	-	(1,102)	(1,102)
Balance at 31 March 2021	14,163	408	1,868	16,440

E. Condensed Full Year Statements of Cash Flows

	Note	Group	
		12 months	12 months
		ended 31 March 2022	ended 31 March 2021
		S\$'000	S\$'000
Operating activities			
Profit before income tax		3,266	3,856
Adjustments for:			
Amortisation of intangible assets		100	101
Loss allowance on trade receivables	14	231	283
Gain on lease modification		-	(2)
Gain on derecognition of financial assets		(471)	-
Loss/(Gain) on disposal of financial asset at FVTPL		34	(5)
Gain on disposal of plant and equipment		-	(1)
Plant and equipment written off		4	2
Depreciation of plant and equipment		73	36
Depreciation of ROU assets		478	555
Bad debt recovered		-	(2)
Fair value gain on financial asset at FVTPL		(387)	(1,281)
Share of results of joint venture, net of tax		3	(10)
Impairment loss on joint venture		90	12
Impairment loss on goodwill	12	339	-
Dividend income from financial asset at FVTPL		(336)	(189)
Rental concession		-	(122)
Bad debts written off		3	25
Written back of liabilities		-	(25)
Interest income		(21)	(74)
Interest expense		86	72
Provision for reinstatement cost no longer required		(4)	(10)
Operating cash flows before working capital changes		3,488	3,221
Working capital changes:			
Inventories		78	275
Trade and other receivables		(141)	(138)
Contract assets and contract liabilities		(74)	107
Prepayments		7	(13)
Trade and other payables		(168)	126
Cash generated from operations		3,190	3,578
Income tax paid		(334)	(537)

E. Condensed Full Year Statements of Cash Flows (cont'd)

	Group	
	12 months ended 31 March 2022	12 months ended 31 March 2021
Note	S\$'000	S\$'000
Net cash from operating activities	2,856	3,041
Investing activities		
Acquisition of subsidiaries, net of cash acquired	-	(120)
Advance payment for acquisition of subsidiary	(300)	-
Dividend income from joint venture	20	23
Dividend income from financial assets at FVTPL	336	189
Investment in joint ventures	-	(207)
Advances to joint venture	(25)	-
Interest received	6	18
Disposal of financial asset at FVTPL	856	1,244
Investment in financial asset at FVTPL	(680)	(3,392)
Additions to ROU asset	-	(45)
Additions to intangible asset	(27)	(6)
Proceeds from the disposal of plant and equipment	-	1
Purchase of plant and equipment	(203)	(80)
Net cash used in investing activities	(17)	(2,375)
Financing activities		
Repayments of principal portion of lease liabilities	(494)	(420)
Repayments of interest portion of lease liabilities	(30)	(50)
Proceeds from bank borrowings	2,500	2,500
Interest paid for bank borrowings	(58)	(21)
Repayment of bank borrowings	(2,735)	-
Dividends paid to owners of the parent	(2,204)	(1,102)
Dividends paid to non-controlling interest	(135)	(180)
Net cash (used in) / from financing activities	(3,156)	727
Net change in cash and cash equivalents	(317)	1,393
Cash and cash equivalents at beginning of financial year	6,657	5,265
Effect of foreign exchange rate charges on cash and cash equivalents	(1)	(1)
Cash and cash equivalents at end of financial year	6,339	6,657

F. Notes to the Condensed Interim Consolidated Financial Statements

1. Corporate information

Medinex Limited (the “**Company**”) is a public limited company incorporated and domiciled in Singapore. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) on 7 December 2018. These condensed interim consolidated financial statements as at and for the six months ended 31 March 2022 comprise the Company and its subsidiaries (collectively, the “**Group**”). The primary activity of the Company is that of an investment holding company.

The principal activities of the Group are:

- (a) providing business support services;
- (b) providing medical support services
- (c) providing pharmaceutical services; and
- (d) providing medical services

2. Basis of Preparation

The condensed interim financial statements for the financial year ended 31 March 2022 have been prepared in accordance with SFRS(I) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position since the last annual financial statement for the year ended 31 March 2021 and performance of the Group since the last financial statement for the period ended 30 September 2021.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore dollar which is the Company’s functional currency.

2.1. New and amended standards adopted by the Group

A number of amendments to Standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2. Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 March 2021.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

2. Basis of Preparation (cont'd)

2.2. Use of judgements and estimates (cont'd)

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is as below:

- Revenue recognition

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are included in the following :

- Impairment of investment in subsidiaries
- Impairment of goodwill
- Loss allowance for trade and other receivables
- Fair value measurement of unquoted securities

3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4. Segment and revenue information

The Group is organised into the following main business segments:

- Segment 1: Medical support services
- Segment 2: Business support services
- Segment 3: Pharmaceutical
- Segment 4: Medical services

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

4. Segment and revenue information

4.1. Reportable segments

Business segment	Medical support services	Business support services	Pharmaceutical services	Medical services	Unallocated Expenses	Consolidated
1 October 2021 to 31 March 2022	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)
Revenue						
External revenue	1,946	1,605	1,699	998	-	6,187
Profit from operations						
Share of results from joint Venture, net of tax	-	-	-	-	(13)	(13)
Interest income	-	-	-	-	4	4
Inventories and consumables used	2	-	1,457	272	-	1,731
Finance costs	18	1	13	8	1	41
Amortisation and depreciation expense	108	14	43	124	63	352
Employee benefits expense	565	27	-	396	1,458	2,446
Income tax expense	77	106	-	(8)	2	177
Reportable segment profit/(loss) before income tax	1,103	1,283	70	136	(1,614)	978
Net profit/(loss) for the financial period after tax	1,026	1,177	67	144	(1,616)	798

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

4. Segment and revenue information (Cont'd)

4.1. Reportable segments (Cont'd)

Business segment	Medical support services	Business support services	Pharmaceutical services	Medical services	Unallocated Expenses	Consolidated
1 October 2020 to 31 March 2021	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Revenue						
External revenue	1,862	1,348	1,683	913	(2)	5,804
Profit from operations						
Share of results from joint Venture, net of tax	-	-	(11)	-	53	42
Interest income	2	-	2	-	55	59
Inventories and consumables used	(7)	-	1,474	224	-	1,691
Finance costs	28	2	4	11	1	46
Amortisation and depreciation expense	85	129	31	131	(34)	342
Employee benefits expense	382	45	293	415	1,334	2,469
Income tax expense	117	26	(32)	5	2	118
	-	-	-	-	-	-
Reportable segment profit/(loss) before income tax	1,189	978	(173)	145	119	2,258
Net profit/(loss) for the financial period after tax	1,072	952	(141)	140	117	2,140

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

4. Segment and revenue information (Cont'd)

4.1. Reportable segments (Cont'd)

Business segment	Medical support services	Business support services	Pharmaceutical services	Medical services	Unallocated Expenses	Consolidated
1 April 2021 to 31 March 2022	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Revenue						
External revenue	3,794	2,845	3,405	1,949	-	11,993
Profit from operations						
Share of results from joint Venture, net of tax	-	-	-	-	(3)	(3)
Interest income	-	-	-	-	21	21
Inventories and consumables used	12	-	2,914	499	-	3,425
Finance costs	48	1	16	19	2	86
Amortisation and depreciation expense	177	28	67	253	126	651
Employee benefits expense	1,092	721	281	809	1,587	4,490
Income tax expense	177	180	-	13	-	370
Reportable segment profit/(loss) before income tax	2,569	2,346	43	303	(1,995)	3,266
Net profit/(loss) for the financial period after tax	2,392	2,166	43	291	(1,996)	2,896

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

4. Segment and revenue information (cont'd)

4.1. Reportable segments (cont'd)

Business segment	Medical support services	Business support services	Pharmaceutical services	Medical services	Unallocated Expenses	Consolidated
1 April 2020 to 31 March 2021	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Revenue						
External revenue	3,474	2,485	3,192	1,634	-	10,785
Profit from operations						
Share of results from joint Venture, net of tax	-	-	(11)	-	21	10
Interest income	2	-	2	-	70	74
Inventories and consumables used	-	-	2,708	415	-	3,123
Finance costs	34	4	7	26	1	72
Amortisation and depreciation expense	168	190	58	257	20	693
Employee benefits expense	750	203	562	826	1,946	4,287
Income tax expense	176	116	-	9	1	303
Reportable segment profit/(loss) before income tax	2,417	1,945	(146)	239	(599)	3,856
Net profit/(loss) for the financial period after tax	2,241	1,829	(146)	230	(601)	3,553

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

4. Segment and revenue information (cont'd)

4.1. Reportable segments (cont'd)

Business segment	Medical support services	Business support services	Pharmaceutical services	Medical services	Unallocated Expenses	Consolidated
1 October 2021 to 31 March 2022	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
<u>Other information:</u>						
Additions to non-current assets						
-plant and equipment	106	7	33	6	11	163
-intangible assets	13	-	13	-	-	26
-ROU assets	220	-	103	-	-	323
Segment assets	570	1,638	3,638	978	16,157	22,981
Segment liabilities	1,977	640	1,684	621	583	5,505
1 October 2020 to 31 March 2021						
<u>Other information:</u>						
Additions to non-current assets						
-plant and equipment	4	16	4	2	13	39
-intangible assets	6	-	-	-	-	6
-ROU assets	-	-	86	17	66	169
Investment in Joint Venture	-	-	171	-	125	296
Segment assets	5,102	5,392	2,467	2,897	7,573	23,431
Segment liabilities	3,469	615	704	1,017	699	6,504

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

4. Segment and revenue information (cont'd)

4.1. Reportable segments (cont'd)

Business segment	Medical support services	Business support services	Pharmaceutical services	Medical services	Unallocated Expenses	Consolidated
1 April 2021 to 31 March 2022	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
<u>Other information:</u>						
Additions to non-current assets						
-plant and equipment	125	7	52	7	12	203
-intangible assets	13	-	13	-	-	26
-ROU assets	220	-	103	-	-	323
Segment assets	570	1,638	3,638	978	16,157	22,981
Segment liabilities	1,977	640	1,684	621	583	5,505
1 April 2020 to 31 March 2021						
<u>Other information:</u>						
Additions to non-current assets						
-plant and equipment	6	17	4	4	49	80
-intangible assets	6	-	-	-	-	6
-ROU assets	-	-	86	17	66	169
Segment assets	5,102	5,392	2,467	2,897	7,573	23,431
Segment liabilities	3,469	615	704	1,017	699	6,504

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

4. Segment and revenue information (cont'd)

4.2. Disaggregation of Revenue

Business segment	Medical support services		Business support services		Pharmaceutical services		Medical services		Total	
	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Type of goods or services										
Service fee	1,943	1,862	1,606	1,348	-	-	-	-	3,549	3,210
Sale of medical and pharmaceutical products	-	-	-	-	1,699	1,683	-	-	1,699	1,683
Provision of medical services	-	-	-	-	-	-	999	914	999	914
	<u>1,943</u>	<u>1,862</u>	<u>1,606</u>	<u>1,348</u>	<u>1,699</u>	<u>1,683</u>	<u>999</u>	<u>914</u>	<u>6,247</u>	<u>5,807</u>
Timing of transfer of goods and services										
Point in time	1,894	1,807	1,441	634	1,699	1,683	999	914	6,033	5,039
Over time	49	55	165	714	-	-	-	-	214	769
	<u>1,943</u>	<u>1,862</u>	<u>1,606</u>	<u>1,348</u>	<u>1,699</u>	<u>1,683</u>	<u>999</u>	<u>914</u>	<u>6,247</u>	<u>5,808</u>

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

4. Segment and revenue information (cont'd)

4.2. Disaggregation of Revenue (cont'd)

Business segment	Medical support services		Business support services		Pharmaceutical services		Medical services		Total	
	← 12 months ended →									
	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Type of goods or services										
Service fee	3,793	3,474	2,846	2,484	-	-	-	-	6,639	5,958
Sale of medical and pharmaceutical products	-	-	-	-	3,405	3,193	-	-	3,405	3,193
Provision of medical services	-	-	-	-	-	-	1,949	1,634	1,949	1,634
	<u>3,793</u>	<u>3,473</u>	<u>2,846</u>	<u>2,484</u>	<u>3,405</u>	<u>3,193</u>	<u>1,949</u>	<u>1,634</u>	<u>11,993</u>	<u>10,785</u>
Timing of transfer of goods and services										
Point in time	3,679	3,363	2,262	1,729	3,405	3,193	1,949	1,634	11,295	9,919
Over time	114	110	584	756	-	-	-	-	698	866
	<u>3,793</u>	<u>3,473</u>	<u>2,846</u>	<u>2,485</u>	<u>3,405</u>	<u>3,193</u>	<u>1,949</u>	<u>1,634</u>	<u>11,993</u>	<u>10,785</u>

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

4. Segment and revenue information (cont'd)

A breakdown of sales:

	Financial Year ended 31 Mar 2022 S\$'000	Financial Year ended 31 Mar 2021 S\$'000	Increase / (Decrease) %
(a) Sales reported for first half year	5,806	4,982	16.54%
(b) Operating profit after tax before deducting non-controlling interests reported for first half year	2,096	1,413	48.34%
(c) Sales reported for second half year	6,187	5,804	6.60%
(d) Operating profit after tax before deducting non-controlling interests reported for second half year	800	2,140	(62.62%)

5. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 31 March 2022 and 31 March 2021:

	Group		Company	
	31-Mar-22 S\$'000	31-Mar-21 S\$'000	31-Mar-22 S\$'000	31-Mar-21 S\$'000
<u>Financial assets</u>				
Trade and other receivables	2,121	2,188	207	209
Cash and bank balances	5,823	5,107	3,067	1,243
Fixed Deposit	516	1,550	-	1,038
At fair value through profit or loss	5,573	4,321	5,573	4,320
<u>Financial liabilities</u>				
Trade and other payables	1,315	1,638	2,714	2,231
Lease liabilities	829	1444	-	-
Bank borrowings	2,275	2,511	10	10

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

6. Profit before taxation

6.1. Significant items

	6 months ended		12 months ended	
	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021
	S\$'000	S\$'000	S\$'000	S\$'000
Profit for the financial period/year is stated after charging the following:				
Fair value gain on financial asset at FVTPL	330	(1,281)	(387)	(1,281)
Loss/(Gain) on disposal of investment	34	(5)	34	(5)
Rental income	-	32	(3)	(33)
Rental concession	-	(123)	-	(123)
Government grant	(164)	(253)	(329)	(741)
Interest income	(6)	(17)	(21)	(74)
Loss allowance on trade receivables	211	278	231	283
Bad debts written off	3	25	3	25
Amortisation of intangible assets	54	52	100	101
Depreciation of plant and equipment	44	20	73	36
Depreciation of ROU	253	268	478	555
Cost of service	132	124	208	185
Platform fee	49	70	105	142
Gain on derecognition of financial assets	471	-	471	-
Impairment loss on joint venture	90	12	90	12
Impairment loss on goodwill	339	-	339	-

6.2. Related party transactions

There are no material related party transactions apart from those disclosed elsewhere in the financial statements.

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

7. Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

	6 months ended		12 months ended	
	31 Mar 2022 S\$'000	31 Mar 2021 S\$'000	31 Mar 2022 S\$'000	31 Mar 2021 S\$'000
Current income tax				
- current financial period	178	118	370	303
Total income tax expense recognised in profit or loss	178	118	370	303

8. Dividends

	Group	
	Financial year ended 31 Mar 2022 S\$'000	Financial year ended 31 Mar 2021 S\$'000
Ordinary shares (tax exempt 1-tier)		
- Interim	1,102	1,102
- Final	-	1,102
Total Annual Dividend	1,102	2,204

The Board of Directors proposed that a final tax exempt dividend of \$0.0084 per ordinary share amounting to S\$1.102 million to be paid for the financial year ended 31 March 2022. These dividends have not been recognised as a liability as at the end of the reporting period as it is subject to the approval of the shareholders at the Annual General

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

9. Earnings Per Share

The calculation for earnings per share is based on:

	Group	
	Full Year Ended	
	31-Mar-22 (Unaudited)	31-Mar-21 (audited)
Profit attributable to owners of the Company (S\$'000)	2,807	3,493
Weighted-average number of ordinary shares used in issue during the financial year applicable to earnings per share	131,207,540	131,207,540
Earnings per share (S\$ cents)		
– Basic and diluted	2.14	2.66

The calculations of basic and diluted earnings per share are based on profit attributable to owners of the Company divided by the weighted average number of ordinary shares outstanding during the financial year.

The Group did not have any dilutive potential ordinary shares as at 31 March 2022 and 31 March 2021.

10. Net Asset Value

	Group		Company	
	31-Mar-22 (Unaudited)	31-Mar-21 (Audited)	31-Mar-22 (Unaudited)	31-Mar-21 (Audited)
Net asset value ("NAV")				
NAV (S\$)	17,476,000	16,927,000	17,374,000	16,440,000
Number of ordinary shares in issue	131,207,540	131,207,540	131,207,540	131,207,540
NAV per ordinary share (S\$ cents)	13.32	12.90	13.24	12.53

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

11. Financial assets at fair value through profit and loss ("FVTPL")

	Group		Company	
	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021
	S\$'000	S\$'000	S\$'000	S\$'000
Quoted equity investments	4,315	4,321	4,315	4,321
Unquoted equity investments	1,258	-	1,258	-
	<u>5,573</u>	<u>4,321</u>	<u>5,573</u>	<u>4,321</u>

Movement in financial assets at fair value through profit and loss as follows:

	Group and Company	
	31 Mar 2022	31 Mar 2021
	S\$'000	S\$'000
Balance at beginning of financial year	4,321	887
Fair value gain	387	1,281
Gain on derecognition	471	-
Addition	1,284	3,393
Disposal	(856)	(1,240)
(Loss)/Gain on disposal	<u>(34)</u>	<u>-</u>
Balance at end of financial year	<u>5,573</u>	<u>4,321</u>

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

11.1. Fair value measurement

The Group classifies financial assets measured at fair value using a fair value hierarchy which reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- a) Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1);
- b) Inputs other than quoted prices included within Level 1 which are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices) (Level 2); and
- c) Inputs for the assets or liability which are not based on observable market data (unobservable inputs) (Level 3)

	Fair value measurements using			
	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
	S\$'000	S\$'000	S\$'000	S\$'000
Group				
2022				
<u>Financial assets</u>				
Financial assets, at FVTPL				
-	4,315	-	-	4,315
-	-	-	1,258	1,258
	4,315	-	1,258	5,573
2021				
<u>Financial assets</u>				
Financial assets, at FVTPL				
-	4,321	-	-	4,321
	4,321	-	-	4,321

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

12. Intangible assets

	Customer listing	Goodwill	Software	Web Development	Total
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Group					
Cost					
Balance at 1 October 2021	430	6,844	-	6	7,280
Additions	-	-	27	-	27
Balance at 31 March 2022	430	6,844	27	6	7,307
Accumulated amortisation and impairment loss					
Balance at 1 October 2021	226	-	-	1	227
Amortisation for the financial year	45	-	9	1	55
Impairment loss for financial year	-	339	-	-	339
Balance at 31 March 2022	271	339	9	2	621
Net carrying amount					
Balance at 31 March 2022	159	6,505	18	4	6,686
Remaining useful life at end of financial year	1-5 years	Indefinite	2 years	3 years	

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

12. Intangible assets (cont'd)

	Customer listing	Goodwill	Web development	Total
	S\$'000	S\$'000	S\$'000	S\$'000
Group				
Cost				
Balance at 1 October 2020	430	6,844	-	7,274
Additions	-	-	6	6
Balance at 31 March 2021	430	6,844	6	7,280
Accumulated amortisation				
Balance at 1 October 2020	81	-	-	81
Amortisation for the financial year	100	-	1	101
Balance at 31 March 2021	181	-	1	182
Net carrying amount				
Balance at 31 March 2021	249	6,844	5	7,098
Remaining useful life at end of financial year	1-5 years	Indefinite	4 years	

Amortisation expense was included under the line item "depreciation and amortisation expenses" of the condensed interim and full year consolidated statement of profit or loss and other comprehensive income. Goodwill arising from the business combination were related to the acquisition of subsidiaries that are expected to benefit from the business combination except for Medinex Professional Services Pte. Ltd. ("MPS") and Jo-L Consultus Pte. Ltd. ("Jo-L"), Sen Med Holdings Pte. Ltd. and its subsidiaries ("SMH"), Medinex Advisory Pte. Ltd. and SKI Consultancy Pte. Ltd. ("SKI Group") are determined as one cash generating unit ("CGU") respectively. Before recognition of impairment loss, the carrying amount of goodwill had been allocated as follows:

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

13. Intangible assets (cont'd)

	31 Mar 2022	31 Mar 2021
	S\$'000	S\$'000
CGUs		
Nex Healthcare Pte. Ltd. (" Nex ")	2,390	2,390
Acctax Management Consultancy Pte. Ltd. (" Acctax ")	335	335
MPS and Jo-L	914	914
SMH	1,266	1,266
Ark Leadership & Learning Pte. Ltd. (" Ark Leadership ")	872	872
SKI Group	1,067	1,067
	<u>6,844</u>	<u>6,844</u>

Impairment test of goodwill and customer listing as at 31 March 2022, the recoverable amount of the CGU has been determined based on value-in-use calculations using management-approved discounted cash flow projections covering 5 years (2021: 5 years). Management assessed 5 years cash flows and projection to terminal year for the financial forecast of the CGU as appropriate considering the management's business plan in the near future. The key assumptions for the discounted cash flow projections are those regarding the revenue growth rates and discount rates as follows:

	<u>Revenue growth rates</u>		<u>Pre-tax discount rates</u>	
	<u>2022</u>	<u>2021</u>	<u>2022</u>	<u>2021</u>
Nex	-1% to 1%	1% to 12%	14%	14%
Acctax	2% to 4%	0% to 8%	12%	12%
MPS and Jo-L	2%	0% to 2%	16%	17%
SMH	3% to 20%	1% to 99%	15%	17%
Ark Leadership	-23% to 31%	0% to 82%	16%	17%
SKI Group	2%	2%	15%	17%

Terminal growth rate of 0.5% (2021: 0.5%) was applied to all CGUs in the cash flows projection to terminal year.

Revenue growth rates and terminal growth rates – The forecasted growth rates are based on management's expectations for each CGU from historical trends as well as average growth rates of the industry.

Discount rates - Management estimates discount rate using pre-tax rates that reflect current market assessments of the time value of money and the risks specific to the CGU.

During the financial year, one of the operating unit in the medical services segment was facing stiff competition from local players, which resulted an adverse impact on the projected value-in-use of the operation concerned. Consequently, the Group has made impairment loss of goodwill amounted to S\$0.34 million. The impairment loss was fully allocated to SMH's goodwill.

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

13. Investments in subsidiaries

	Company	
	31 Mar 2022	31 Mar 2021
	S\$'000	S\$'000
Unquoted equity shares, at cost		
Balance at beginning of financial year	11,173	11,173
Additions during the financial year	-	1
Disposal during the financial year	(84)	-
Allowance for impairment loss	(492)	(289)
Balance at end of financial year	10,597	10,884
Movement of allowance of impairment loss in subsidiaries		
Balance at beginning of financial year	289	250
Impairment losses during the financial year	287	39
Write off impairment during the financial year	(84)	-
Balance at end of financial year	492	289

During the financial year, one of the operating units in the medical services segment was facing stiff competition from local players, which resulted an adverse impact on the projected value-in-use of the operation concerned. Consequently, the Company has made impairment loss of cost of investment in SMH amounting to S\$0.29 million during the financial year.

SKI Consultancy Pte Ltd was struck off on 04 May 2021 and derecognised cost of investment of S\$0.08 million during the financial year.

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

14. Trade and other receivables

	Group		Company	
	31 Mar 2022 S\$'000	31 Mar 2021 S\$'000	31 Mar 2022 S\$'000	31 Mar 2021 S\$'000
Non-current assets				
Other receivables				
- Joint venture	-	589	-	589
Current assets				
Trade receivables				
- third parties	2,583	2,331	-	-
- subsidiary	-	-	-	42
- related parties	132	96	-	-
	2,715	2,427	-	42
Loss allowance on receivables	(697)	(492)	-	-
	2,018	1,935	-	42
Other receivables				
- third parties	3	124	2	1
- subsidiary	-	-	200	129
- joint venture	-	8	-	8
- related parties	-	1	-	-
Deposits	100	70	5	6
Grant receivables in respect of Jobs Support Scheme ("JSS")	-	50	-	23
	2,121	2,188	7	209
	2,121	2,777	207	798

15. Plant and equipment

During the six months ended 31 March 2022, the Group acquired assets amounting to \$157,439 (31 March 2021: \$42,751) and disposed of assets amounting to \$Nil (31 March 2021: \$1,000).

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

16. Borrowings

	Group		Company	
	31 Mar 2022 S\$'000	31 Mar 2021 S\$'000	31 Mar 2022 S\$'000	31 Mar 2021 S\$'000
Non-current				
Unsecured				
Term loan I	-	2,292	-	-
Term loan II	1,779	-	-	-
	<u>1,779</u>	<u>2,292</u>	<u>-</u>	<u>-</u>
Current				
Unsecured				
Term loan I	-	209	-	-
Term loan II	486	-	-	-
Revolving working capital line	10	10	10	10
	<u>496</u>	<u>219</u>	<u>10</u>	<u>10</u>
	<u>2,275</u>	<u>2,511</u>	<u>10</u>	<u>10</u>

Revolving working capital line is repayable on demand, unsecured and is arranged at floating rates.

Term loan I & II are arranged at fixed rate and is repayable within over 60 months. It is supported by corporate guarantee provided by the Company. The carrying amount of the Group's non-current term loans approximate their fair values as the current lending rates for similar types of lending arrangements are not materially different from the rates obtained by the Group

17. Share Capital

	Group and Company			
	31 Mar 2022	31 Mar 2021	31 Mar 2022	31 Mar 2021
	Number of ordinary shares		S\$	S\$
Issued and fully-paid:				
Balance at beginning and end of financial year	131,207,540	131,207,540	14,163,317	14,163,317

F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

17. Share Capital (cont'd)

There was no change in the Company's share capital since 30 September 2021.

The Company did not hold any treasury shares as at 31 March 2022.

There were no outstanding options, convertibles, treasury shares or subsidiary holdings as at 31 March 2022 and 31 March 2021.

There was no sale, transfer, disposal, cancellation and/or use of treasury shares or subsidiary holdings during, and at the end of, the financial year ended 31 March 2022.

18. Subsequent events

There are no known subsequent events which have led to adjustments in this set of interim financial statements.

On 1 April 2022, the Company had acquired the entire and issued paid-up share capital in Carlin Management Services Pte. Ltd. ("**CMS**"), a company incorporated in Singapore which is in the business of provision of accounting, tax and corporate secretarial services, for a consideration of S\$3,000,000 (the "**Consideration**"). The Consideration is satisfied by a cash consideration of S\$2,400,000, with the remaining S\$600,000 to be satisfied by issuance of 2,666,667 new shares in the Company, at fair value of \$0.225 per ordinary share, upon meeting the profit guarantee as stated in the Company's announcement dated 25 March 2022 (the "**Announcement**"). Please refer to the Announcement for more details.

The financial effects of the above transactions have not been included in this interim financial statements for the 6 months ended 31 March 2022. The operating results and assets and liabilities of the company will be reflected in the first half of the 2023 financial statements.

G. Other Information Required Pursuant to Appendix 7C of the Catalyst Rules

1. **Whether the figures have been audited, or reviewed and in accordance with which auditing standard or practice.**

The condensed consolidated statement of financial position of Medinex Limited and its subsidiaries as at 31 March 2022 and the related condensed consolidated profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended and certain explanatory notes have not been audited or reviewed.

2. **A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:**

- (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial year reported on, including (where applicable) seasonal or cyclical factors; and**
- (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial year reported on**

Review for the performance of the Group for the twelve months ended 31 March 2022 ("FY2022") as compared to the twelve months ended 31 March 2021 ("FY2021")

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Revenue

The Group recorded an increase in revenue of approximately S\$1.21 million or approximately 11.20% for FY2022 as compared to FY2021. Our subsidiary, Nex, which is primarily involve in providing pharmaceutical services and medical support services, recorded an increase in revenue of S\$0.21 million arising mainly from the higher demand in pharmaceutical products. Another subsidiary, SMH, has recorded an increase in revenue by S\$0.19 million arising from the increase in demand for health screening services and general medical services attributed by opening of the Singapore border which allowed the entry of new foreign workers. Ark Leadership, another subsidiary of the Company has also recorded an increase in revenue of S\$0.14 million due to implementation of human resources and marketing projects for customers under the Enterprise Development Grant ("EDG"). The main increase in revenue of S\$0.67 million mainly arose from professional services in accounting, taxation and corporate secretarial provided by Medinex Healthcare Pte Ltd, Medinex Advisory Pte Ltd ("**Medinex Advisory**"), Medinex Corporate Services Pte Ltd and Acctax.

Other items of income

Other income, which comprised mainly of fixed deposits interest, government grants, fair value gain on financial asset at FVTPL and rental income, decreased by approximately S\$0.90 million in FY2022 as compared to FY2021. The decrease was mainly due to (a) the decrease in fair value gain on investment in financial asset at FVTPL of approximately S\$0.89 million, and (b) the decrease in government grants and rental rebate of an aggregate amount of approximately S\$0.53 million as a result of the reduction in government grants and rental rebate, (c) the decrease in interest income from fixed deposit approximately S\$ 0.01 million and partially offset by (a) increase in gain on derecognition of financial asset approximately S\$0.47 million, and (b) increase in referral fee of approximately S\$0.06 million.

Items of expenses

Inventories and consumables used and changes in inventories increased by approximately S\$0.30 million due to the increase in demand for medical services and pharmaceutical products.

Amortisation and depreciation expenses decreased by approximately S\$0.04 million in FY2022 as compared to FY2021 due to a decrease in depreciation of ROU assets and amortisation of intangible assets of approximately S\$0.08 million and partially offset by the increase in depreciation charges of fixed assets of S\$0.04 million.

Employee benefits expense increased by approximately S\$0.20 million, or approximately 4.74% from FY2021 to FY2022 as a result of the recruitment of additional manpower in Malaysia to expand the Malaysia team as part of the long-term strategy in respect of cost saving measures.

Loss allowance on trade receivables decreased by approximately S\$0.05 million or 18.37% due to lower impairment provisions in FY2022 as compared to FY2021.

Finance cost increased by approximately S\$0.01 million or approximately 19.44% due to higher interest on the bank loan in FY2022.

Share of results of joint ventures net of tax decreased by approximately S\$0.01 million due to losses recorded in Zenmedic Pte Ltd and J-Connect Pte Ltd ("**J-Connect**").

Profit before income tax

As a result of the abovementioned, profit before income tax decreased by approximately S\$0.59 million or approximately 15.30%.

Income tax expense

Income tax expenses increased by approximately S\$0.07 million or approximately 22.11% despite a decrease in the profit before income tax in view that FY2021 had lower taxable profits due to the higher government grants provided and fair value gain on investment in financial asset at FVTPL recorded in which both are not taxable.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

The comparative performance for both the assets and liabilities are based on the Group's financial statements as at 31 March 2022 and 31 March 2021.

Non-current assets

The Group's non-current assets comprises of plant and equipment, ROU assets, intangible assets, investment in joint ventures, financial assets at FVTPL and other receivables.

The Group's intangible assets (which relates to customer relationships) decreased by approximately S\$0.41 million mainly due to (a) the amortisation of intangible assets of the Company's subsidiaries, Ark Leadership, Medinex Advisory, Nex and Medinex Professional Services Pte Ltd of approximately S\$0.10 million and (b) impairment of goodwill for SMH of approximately S\$0.34 million in FY2022 which were partially offset by addition of intangible assets of approximately S\$0.03 million.

The Group's investment in joint ventures decreased by approximately S\$0.11 million due to the loss from Zenmedic and J-Connect of approximately S\$0.14 million and partially offset by the profit from HEPL of approximately S\$0.03 million in FY2022.

The Group's ROU assets decreased by approximately S\$0.58 million due to depreciation expenses of approximately S\$0.48 million and lease modification of approximately S\$0.42 million and partially offset by the

entry of new lease agreements of approximately S\$0.32 million.

The Group's plant and equipment increased by approximately S\$0.12 million mainly due to the purchase of office equipment, renovation and computer equipment amounting to S\$0.20 million and partially offset by the depreciation of plant and equipment amounting to S\$0.08 million.

Financial assets at FVTPL increased by approximately S\$1.25 million due to (a) increase in investment in quoted and unquoted securities of approximately S\$1.28 million, (b) revaluation gain of the quoted securities of approximately S\$0.39 million and (c) gain on derecognition of financial asset at FVTPL of approximately S\$0.47 million, which were partially offset by the disposal of quoted securities of approximately S\$0.86 million in FY2022 and loss on disposal of quoted securities of approximately S\$ 0.03.

Other receivables decreased by approximately S\$0.59 million due to loan repayment from Company's joint venture entity, Zenmedic.

Current assets

Inventories decreased by approximately S\$0.08 million mainly due to an increase in demand for medical services and pharmaceutical products.

Trade receivables and other receivables increased by approximately S\$0.07 million due to (a) increase in trade receivables of S\$0.29 million, (b) increase in deposits of approximately S\$0.03 million due to the security deposits for new lease agreements and partially offset by (a) increase in loss allowance on receivables amounting to S\$0.20 million and (b) decrease in JSS grant receivables amounting to approximately S\$0.05 million.

Contract assets increased by approximately S\$0.05 million due to the increase in accrued revenue.

Prepayments increased by approximately S\$0.29 million mainly due to the payment of the deposit in relation to the entry into a binding term sheet in respect of the proposed acquisition of CMS which was announced on 2 March 2022.

Non-current liabilities

Non-current lease liabilities decreased by approximately S\$0.49 million mainly due to the repayment of lease liabilities in FY2022.

The Group's bank borrowing decreased by approximately S\$0.51 million due to the repayment of bank loan in FY2022.

Current liabilities

Trade and other payables decreased by approximately S\$0.17 million mainly due to decrease in (a) deferred grant income of approximately S\$0.08 million, (b) employee benefits expense of approximately S\$0.07 million and (c) other payables of approximately S\$0.02 million.

Contract liabilities decreased by approximately S\$0.03 million due to the increase in deferred income amounting to approximately S\$0.03 million, and partially offset by the decrease in advance payment received from customers of approximately S\$0.06 million.

The Group's bank borrowing increased by approximately S\$0.28 million due to the bank borrowings which are due and repayable in the next 12 months.

Current income tax payable increased by S\$0.04 million mainly due to higher taxable profits in FY2022 as a result of lower government grants provided and lower fair value gain on investment in financial asset at FVTPL recorded in FY2022, in which both are non-taxable.

Equity

The increase in retained earnings of S\$0.61 million as at 31 March 2022 as compared to 31 March 2021 was mainly due to profit earned of approximately S\$2.81 million and partially offset by the dividend payment of approximately S\$2.20 million in FY2022.

CONSOLIDATED STATEMENT OF CASH FLOWS

The Group recorded net cash generated from operating activities of approximately S\$2.86 million in FY2022, mainly due to operating cash flow before changes in working capital of approximately S\$3.49 million, and adjusted for net working capital outflow of approximately S\$0.30 million and income tax paid of approximately S\$0.33 million. Our net working capital outflow was mainly due to increase in (a) trade and other receivables of approximately S\$0.14 million, and (b) contract assets and contract liabilities of approximately S\$0.07 million, which were partially offset by decrease in (a) prepayments of approximately S\$0.01 million, (b) inventories of approximately S\$0.07 million and (c) trade and other payables of approximately S\$0.17 million.

Net cash used in investing activities of approximately S\$0.02 million FY2022 was mainly due to (a) the investment of financial asset at FVTPL of approximately S\$0.68 million, (b) purchase of plant and equipment and intangible assets of an aggregate amount of approximately S\$0.23 million, (c) advance payment for acquisition of subsidiaries approximately S\$0.30 million, and (d) advances to joint venture of approximately S\$0.03 million, which were partially offset by (a) dividend income financial asset at FVTPL and interest received of an aggregate amount of approximately S\$0.36 million, and (b) disposal of financial assets at FVTPL approximately S\$0.86 million.

Net cash used in financing activities amounted to approximately S\$3.16 million, mainly due to (a) dividend payout to shareholders of the Company and non-controlling interests of SMH of approximately S\$2.34 million, (b) repayment of principal portion of lease liabilities and its interest portion of an aggregate of approximately S\$0.52 million, (c) repayment of bank borrowings and its interest portion of an aggregate of approximately S\$2.79 million, which were partially offset by an increase in bank borrowings of approximately S\$2.50 million.

As a result of the abovementioned, the Group recorded a net decrease in cash and cash equivalents of approximately S\$0.32 million in FY2022.

3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

Not applicable as no forecast or prospect statement has been disclosed previously.

4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

On 24 March 2022, the Civil Aviation Authority of Singapore announced that Singapore will reopen its borders on 1 April 2022 and the growth prospects remain strong given the continued global economic recovery. With more returning patients, the Group expects more new clinic set-ups, hence greater demand for healthcare support services. Our newly established presence at Farrer Park Medical Centre will give an added advantage

to reach out to these new doctors.

To pursue long term and sustainable growth, the Group remains to explore opportunities for expansion of existing through acquisition and strategic alliances apart from the organic growth in the existing business. The Group has successfully acquired CMS since 1 April 2022. This provides the Group the opportunity to bring its business support services to the new customer segments such as the logistics segment, which experienced a spike in growth rate especially during the Covid-19 period.

The Group will continue to strengthen its IT capability to digitalise some of the processes so that we can provide a better service delivery while adopting a more prudent manpower strategy.

5. Dividend

If a decision regarding dividend has been made: -

- (a) Whether an interim (final) ordinary dividend has been declared (recommended); and

Yes.

The following interim dividend was declared on 12 November 2021 for the six (6) months period ended 30 September 2021 and paid on 06 December 2021.

Name of Dividend	Interim
Dividend Type	Ordinary
Dividend Amount per Share (in S\$ cents)	0.84 cents per ordinary share (one tier tax)
Tax Rate	Tax exempt

The Directors are recommending a final dividend for FY2022 which will be subject to shareholders' approval at the forthcoming annual general meeting to be held in July 2021 ("**Annual General Meeting**").

Name of Dividend	Proposed Final
Dividend Type	Ordinary
Dividend Amount per Share (in S\$ cents)	0.84 cents per ordinary share (one tier tax)
Tax Rate	Tax exempt

If approved, the final dividend of 0.84 cents per ordinary share and the interim dividend of 0.84 cents per ordinary share (paid on 30 September 2022) would bring the total dividends for FY2022 to 1.68 cents per ordinary share.

- (b) (i) Amount per share (cents)

Please refer to paragraph 5(a).

- (ii) Previous corresponding period (cents)

Name of Dividend	Interim
Dividend Type	Ordinary
Dividend Amount per Share (in S\$ cents)	0.84 cents per ordinary share (one tier tax)
Tax Rate	Tax exempt

Name of Dividend	Final
Dividend Type	Ordinary
Dividend Amount per Share (in S\$ cents)	0.84 cents per ordinary share (one tier tax)
Tax Rate	Tax exempt

- (c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (if the dividend is not taxable in the hands of shareholders, this must be stated.)

Please refer to paragraph 5(a).

- (d) The date the dividend is payable.

The date of payment of the proposed final dividend, if approved at the Annual General Meeting, will be announced at a later date.

- (e) The date on which Registrable Transfers received by the Company (up to 5.00pm) will be registered before entitlements to the dividend are determined.

The record date will be announced at a later date.

6. Interested Party Transactions

The Company does not have a general mandate from shareholders for interested person transactions.

7. Use of IPO Proceeds

The Company refers to the net cash proceeds amounting to S\$5.28 million (excluding cash listing expenses of approximately S\$1.22 million) raised from the IPO on the Catalist Board of SGX-ST on 7 December 2018.

As at the date of the announcement, the status on the use of the IPO net proceeds is as follows:

	Amount allocated (S\$'000)	Amount utilised (S\$'000)	Balance (S\$'000)
Expand our Group's business operations via acquisitions, joint ventures and/or strategic partnerships	4,000.00	3,532.50 ⁽¹⁾	467.50
Working Capital	1,316.00	786.00 ⁽²⁾	530.00
Total	5,316.00	4,318.50	997.50

Notes:

- (1) Utilised for the following:-
(a) acquisition of SMH - S\$1,732,500;
(b) acquisition of Ark Leadership - S\$600,000; and
(c) acquisition of SKI Group. and Medinex Advisory – S\$1,200,000
- (2) Utilised for the payment of listing expenses of S\$36,000 and the provision of the convertible loan amount of S\$750,000 to Singapore Paincare Holdings Limited.

The utilisation is in accordance with the intended use as stated in the Company's offer document dated 30 November 2018.

8. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1)

The Company confirms that it has procured undertaking from all its directors and executive officers (in the format as set out in Appendix 7H) under Rule 720(1) of the SGX-ST Listing Manual Section B: Rules of Catalyst ("Catalist Rules").

9. Disclosure of persons occupying managerial positions in the issuer or any of its principal subsidiaries who are related to a director, CEO or substantial shareholder

Name	Age	Family relationship with any director, chief executive officer or substantial shareholder	Current position and duties, and the year the position was first held	Details of changes in duties and position held, if any, during the year
Karunanithi s/o Letchumanan	61	Spouse of Jessie Low Mui Choo, the Executive Director and Chief Executive Officer of the Company	Director of Medinex Corporate Services Pte. Ltd. since 2 May 2017 and Medinex Healthcare Pte. Ltd. since 5 July 2018. Involved in the marketing and business development of the two subsidiaries of the Group.	NIL
Low Mui Keow, Valerie (Lu Mei Jiao, Valerie)	50	Sister of Jessie Low Mui Choo, the Executive Director and Chief Executive Officer of the Company	Business Development Director of the Group since 6 May 2019. Involved in overseeing the business development activities of the Group.	NIL

BY ORDER OF THE BOARD

Jessie Low Mui Choo
Executive Director and Chief Executive Officer
30 May 2022